TP53 and keratoconus: This compensational mechanism of the ERBB family could possibly play a role in the resistance of an EGFR inhibitor therapy in PDAC patients and in attenuated PDAC development in EGFR/TP53‐depleted KC mice (Ardito et al., 2012; Navas et al., 2012).